Literature DB >> 22351566

Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure.

Jun-ichi Kusaba1, Noriko Kajikawa, Hiromu Kawasaki, Yuji Kurosaki, Tetsuya Aiba.   

Abstract

To examine the mechanism accounting for the diverse alteration of hepatic metabolism of CYP3A substrates observed with renal function being severely impaired, the hepatic drug metabolizing activity was evaluated using liver microsomes prepared from rats with glycerol-induced acute renal failure (ARF). Midazolam, nifedipine and rifabutin were employed as representative CYP3A substrates. When the Michaelis-Menten parameters, K(m) and V(max) , were examined in the incubation study, the K(m) values of midazolam and nifedipine in ARF rats were shown to decrease by 50.9% and 29.9% compared with the normal value, respectively. The V(max) values of midazolam and nifedipine in ARF rats also decreased by 49.3% and 28.0%, respectively, showing that their decreased K(m) values accompanied the decreased V(max) values. The parameters of nifedipine seemed to alter to a lesser extent than those of midazolam. As for rifabutin metabolism, the decrease in the K(m) value was observed in ARF rats, but it did not accompany the decrease in the V(max) value. Then, the hepatic expressions of the CYP3A subfamily were examined with western blotting using anti-CYP3A1 and anti-CYP3A2 antibodies. It was revealed that the hepatic expression of CYP3A2 decreased, while that of CYP3A1 was unaffected. Additionally, a band signal deduced to originate from CYP3A9 was clearly detected in ARF, but not in normal rats. Considering each substrate having different specificities for CYP3A subfamily member proteins, individual alterations of hepatic CYP3A subfamily expression seem to underlie the diverse alterations of hepatic metabolism of CYP3A substrates in ARF rats.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351566     DOI: 10.1002/bdd.1774

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  6 in total

Review 1.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

2.  Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.

Authors:  Yosuke Suzuki; Hiroki Itoh; Fuminori Sato; Kanako Kawasaki; Yukie Sato; Takashi Fujioka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

3.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

4.  Evaluation of Zuo-Gui Yin Decoction Effects on Six CYP450 Enzymes in Rats Using a Cocktail Method by UPLC-MS/MS.

Authors:  Bangzhen Hong; Shizhong Hong; Xuerui Hu; Fan He; Xiaoxiao Shan; Lei Wang; Weidong Chen
Journal:  Biomed Res Int       Date:  2022-08-26       Impact factor: 3.246

5.  BDE47 induces rat CYP3A1 by targeting the transcriptional regulation of miR-23b.

Authors:  Zhenzhen Sun; Zhan Zhang; Minghui Ji; Hongbao Yang; Meghan Cromie; Jun Gu; Chao Wang; Lu Yang; Yongquan Yu; Weimin Gao; Shou-Lin Wang
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

6.  Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease.

Authors:  Ryota Tanaka; Yosuke Suzuki; Hiroshi Watanabe; Takashi Fujioka; Kenshiro Hirata; Toshitaka Shin; Tadasuke Ando; Hiroyuki Ono; Ryosuke Tatsuta; Hiromitsu Mimata; Toru Maruyama; Hiroki Itoh
Journal:  Clin Transl Sci       Date:  2021-05-31       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.